1. Sarcoidosis: the clinical problem;Neville, E.;Postgrad Med,1988
2. Immune aspects of sarcoidosis;Poulter, L.W.;Postgrad Med J,1988
3. Expression plexes in some of these patients most probably reflect a secondary B cell stimulation.2 In addition, there is an increased antigenic presentation by the dendritic cells with release of cytokine mediators such as interleukin-l and tumour necrosis factor-ot (TNF-ot) as well as of alveolar macrophage adhesion molecules in pulmonary sarcoidosis;Chest,1992
4. The relationship between alveolar macrophage TNF, IL-I and PGE2 release, alveolitis and disease severity in sarcoidosis;Pueringer, R.J.; Schwartz, D.A.; Dayton, C.S.; Gilbert, SR, Hunninghake; G.W.;Chest,1993
5. Expression of CD14 correlates with lung function impairment in pulmonary sarcoidosis;Pforte, A.; Schiessler, A.; Gais, P.; Beer, B.; Ehlers, M.; Schutt, C.;Chest; 105: oxidants.'l,1994